C91.01 Acute lymphoblastic leukemia, in remission

Name of the Condition

• Acute lymphoblastic leukemia, in remission
• ICD-10 Code: C91.01

Summary

Acute lymphoblastic leukemia (ALL) in remission is a state where the disease is no longer detectable after treatment, though residual leukemia cells may still be present at low levels. Remission indicates that treatment has effectively reduced the number of abnormal lymphoblasts in the bone marrow and blood, allowing normal blood cell production to resume. This condition requires ongoing monitoring to detect potential relapse.

Causes

The causes of acute lymphoblastic leukemia in remission relate to the underlying genetic mutations that initiated the disease. While treatment may eliminate detectable disease, the original genetic abnormalities in lymphoid precursor cells persist. Environmental exposures, genetic predispositions, or prior therapies may have contributed to the initial development of ALL, and these factors remain relevant for long-term management.

Risk Factors

• Exposure to high levels of radiation
• Certain chemical exposures (e.g., benzene)
• Genetic disorders (e.g., Down syndrome)
• Family history of leukemia
• Prior chemotherapy or radiation therapy
• Weakened immune system (e.g., from HIV or immunosuppressive drugs)

Symptoms

• Fatigue and weakness
• Fever or night sweats
• Unexplained weight loss
• Frequent infections
• Easy bruising or bleeding
• Swollen lymph nodes, liver, or spleen
• Bone or joint pain

Diagnosis

Diagnosis of remission involves repeated blood tests and bone marrow biopsies to assess cell counts and detect residual leukemia cells. Molecular testing, such as polymerase chain reaction (PCR), may identify minimal residual disease (MRD) to confirm remission status. Imaging studies or cerebrospinal fluid analysis may also be used to evaluate organ involvement or central nervous system involvement.

Treatment Options

Treatment during remission typically includes maintenance therapy to prevent relapse, such as low-dose chemotherapy or targeted agents. Clinical trials may offer additional options for high-risk patients. Regular follow-up is essential to adjust treatment based on response and detect early signs of recurrence.

Prognosis and Follow-Up

Prognosis for ALL in remission depends on factors like age, genetic markers, and initial response to treatment. Most patients achieve long-term remission, but relapse can occur. Follow-up includes periodic bone marrow tests, blood work, and imaging to monitor for recurrence. Long-term survivors may require surveillance for late effects of treatment.

Complications

Complications of ALL in remission may include treatment-related side effects, such as organ damage or secondary cancers. Relapse is a primary concern, requiring prompt intervention. Other risks include infections due to immunosuppression or metabolic issues from prior therapies.

Lifestyle & Prevention

Lifestyle modifications, such as maintaining a balanced diet and avoiding infections, support overall health during remission. Preventive measures include adhering to treatment plans, avoiding known carcinogens, and staying up-to-date with vaccinations. Regular exercise and stress management may also aid recovery.

When to Seek Professional Help

Seek medical attention if symptoms like persistent fatigue, unexplained weight loss, or signs of infection occur. Prompt evaluation is necessary for any new or worsening symptoms, as these may indicate relapse or treatment-related complications.

Tips for Medical Coders

Code C91.01 is used when acute lymphoblastic leukemia is documented as being in remission. Documentation should specify remission status, and coders should verify that the condition is not active or in relapse. Ensure alignment with clinical notes to confirm appropriate coding for this specific remission phase.